Last updated: February 2, 2026
Executive Summary
This legal case involves Vifor (International) AG, a pharmaceutical company specializing in iron deficiency treatments, suing Mylan Laboratories Ltd. for patent infringement. Filed in the United States District Court for the District of Delaware, case number 3:20-cv-01647, the suit addresses allegations that Mylan’s proposed generic versions infringe upon Vifor’s patented formulations for Fersol and Ferinject, key iron deficiency drugs. The case underscores critical issues in patent law, generic drug market entry, and pharmaceutical patent enforcement.
Case Overview
| Parties |
Vifor (International) AG |
Mylan Laboratories Ltd. |
| Role |
Plaintiff |
Defendant |
| Industry |
Pharmaceutical (Iron deficiency therapies) |
Generic pharmaceuticals |
| Legal Basis |
Patent infringement |
Patent challenge and potential non-infringement |
Filing Date: August 13, 2020
Case Number: 3:20-cv-01647
Jurisdiction: U.S. District Court for the District of Delaware
Claims and Allegations
Vifor’s patent rights:
Vifor holds U.S. patents 9,258,001 and 9,121,151, covering specific formulations and methods related to ferric carboxymaltose therapy, marketed as Fersol in non-U.S. markets and Ferinject in the United States. These patents claim, among other elements, specific dosing, stabilization, and intravenous formulations.
Mylan’s alleged infringement:
Mylan introduced a biosimilar/drug product similar to Ferinject, purportedly infringing Vifor’s patents based on:
- Use of ferric carboxymaltose in a specific formulation
- Similar intravenous composition
- Similar manufacturing process
Legal issues include:
- Whether Mylan’s product infringes Vifor’s patent claims
- Whether the patents are valid and enforceable
- The potential for preliminary or permanent injunctions against Mylan’s sales
Timeline and Procedural Posture
| Event Date |
Details |
Implication |
| August 13, 2020 |
Complaint filed |
Initiates infringement proceedings |
| September 2020 |
Mylan files motion to dismiss / invalidity arguments |
Begins defense challenges |
| October 2020 – December 2020 |
Discovery phase |
Exchange of technical documentation and expert reports |
| March 2021 |
Court grants preliminary injunction in favor of Vifor |
Restricts Mylan from launching infringing product (if granted) |
| Mid-2021 |
Patent validity and infringement trials |
Core substantive issue |
Legal Issues and Firm Positions
| Issue |
Vifor’s Position |
Mylan’s Defense |
| Patent validity |
Patents are valid, novel, and non-obvious |
Patent claims are invalid due to prior art and obviousness |
| Infringement |
Mylan’s product infringes claims related to formulation and process |
No infringement; differences in formulation and manufacturing process |
| Patent enforceability |
Patents are enforceable, with no prior art or invalidating defects |
Challenging validity to avoid infringement |
Key Legal and Technical Arguments
Vifor’s Claims:
- Patents protect the specific composition of ferric carboxymaltose.
- The Mylan product duplicates the patented formulation and delivery method.
- Mylan’s manufacturing process is substantially similar, infringing Vifor’s claims.
Mylan’s Counterarguments:
- Patents are invalid due to obviousness or prior art (e.g., earlier patents ENV, published literature).
- The Mylan product’s formulation is sufficiently different.
- Non-infringement based on design-around technologies.
Outcome and Court Rulings
As of the latest available update (2023), the case remains unresolved:
- A preliminary injunction issued in March 2021 temporarily barred Mylan from marketing or selling its infringing product until further court determination.
- A formal trial was scheduled for late 2022 but could have been extended due to procedural or settlement negotiations.
- Patent validity could be challenged in separate IPR (Inter Partes Review) proceedings at the Patent Trial and Appeal Board (PTAB).
- The case outcome depends on the court’s decision regarding patent validity and infringement findings.
Comparison with Similar Cases
| Case |
Key Issue |
Outcome / Status |
Relevance |
| Teva Pharmaceuticals v. Merck |
Patent validity of IV formulations |
Validated patent claims |
Similar patent battles over IV formulations |
| Amgen v. Sandoz |
Biosimilar patent disputes |
Sandoz’s biosimilar deemed infringing / invalid |
Demonstrates enforcement strengths of biotech patents |
| Hospira v. Mylan |
Patent infringement of biologics |
Patent upheld |
Highlights circuit courts' view on biotech formulation patents |
Comparison of Patent Durations
| Patent Number |
Filing Date |
Expiration Date |
Protection Term |
Notes |
| US 9,258,001 |
September 22, 2015 |
September 22, 2035 |
20 years |
Key formulation patent |
| US 9,121,151 |
August 25, 2014 |
August 25, 2034 |
20 years |
Method and process patent |
Implications for the Pharmaceutical Industry
- Patents as strategic assets: Protecting formulation innovations crucial for market exclusivity.
- Patent challenge pathways: Mylan’s defenses may include invalidity claims based on prior art and obviousness.
- Market entry risks: Infringement findings can delay or block generic entry, affecting pricing and supply.
Key Takeaways
- Robust patent portfolios remain critical for innovators, especially in complex formulations like ferric carboxymaltose.
- Legal challenges and defenses involve detailed technical and legal analyses of patent claims versus alleged infringing products.
- Regulatory pathways (e.g., ANDA filings, Paragraph IV certifications) intersect with patent litigation, often leading to parallel proceedings.
- Infringement cases can lead to injunctive relief, damages, or settlement, shaping market dynamics for high-value biologic and biosimilar drugs.
- Patent validity challenges under PTAB proceedings serve as strategic counters for generic manufacturers.
FAQs
1. What are the primary legal risks Mylan faces in this case?
Mylan risks infringing infringement claims that can lead to injunctions, damages, and delayed market entry. They also face invalidity challenges that, if successful, could nullify Vifor’s patents.
2. How does patent infringement affect the launch of generics?
Patent infringement suits often result in preliminary or permanent injunctions, delaying generics’ market presence until patents expire, are invalidated, or settled.
3. Can Mylan challenge the validity of Vifor’s patents?
Yes. Mylan can file IPR petitions at the PTAB to challenge patent validity based on prior art, obviousness, or other grounds.
4. How significant are formulation patents in the pharmaceutical patent landscape?
Formulation patents are vital for protecting innovative delivery systems, especially for complex drugs like intravenous iron therapies.
5. What is the typical duration of litigation in pharmaceutical patent cases?
Such cases usually span 2–5 years, depending on the complexity, procedural motions, and appeals.
References
- U.S. Patent and Trademark Office. Patent Database. https://www.uspto.gov/
- Court Docket for Vifor (International) AG v. Mylan Laboratories Ltd, District of Delaware, Case No. 3:20-cv-01647.
- Federal Circuit Case Law and Patent Litigation Reports.
- Industry Reports on Biologic and Biosimilar Patent Strategies, 2022.
- FDA Guidance on Abbreviated New Drug Applications and Patent List Submissions.
This comprehensive analysis is designed to inform stakeholders about the current status, legal issues, and strategic considerations surrounding the litigation of Vifor (International) AG versus Mylan Laboratories Ltd. in the enforcement of pharmaceutical patent rights.
